Assertio Holdings (ASRT) Cost of Revenue (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Cost of Revenue came in at $2.7 million in Q1 2026, down 65.18% year-on-year from $7.8 million in Q1 2025, and down 16.99% quarter-over-quarter from $3.3 million in Q4 2025.
Assertio Holdings (ASRT) Cost of Revenue (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Cost of Revenue across 8 years of filings, most recently posting $2.7 million for Q1 2026.
- Cost of Revenue for Q1 2026 came in at $2.7 million, down 65.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.3 million (down 15.43% YoY), and the FY2025 annual result was $35.4 million, down 9.8% from the prior year.
- Cost of Revenue came in at $2.7 million for Q1 2026 at Assertio Holdings, down from $3.3 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $13.7 million in Q3 2025 to a low of $2.7 million in Q1 2026.
- The 5-year median for Cost of Revenue is $7.1 million (2023), against an average of $7.2 million.
- Across the five-year window, Cost of Revenue soared 104.44% in 2024 and sank 71.87% in 2025, its largest moves.
- Assertio Holdings' Cost of Revenue stood at $6.0 million in 2022, then jumped by 61.64% to $9.7 million in 2023, then climbed by 19.44% to $11.6 million in 2024, then tumbled by 71.87% to $3.3 million in 2025, then slipped by 16.99% to $2.7 million in 2026.
- The last three Cost of Revenue figures came in at $2.7 million (Q1 2026), $3.3 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 696.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 641.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 133.40 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 34.44 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 13.80 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 586.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 155.56 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 52.68 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 222.00 Mn |
| 10 | Assertio Holdings | 151.07 Mn | 79.50 Mn | 7.22 Mn | 2.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.71 Mn |
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 3.27 Mn |
| Dec 31, 2025 | 3.27 Mn |
| Sep 30, 2025 | 13.65 Mn |
| Sep 30, 2025 | 13.65 Mn |
| Jun 30, 2025 | 10.68 Mn |
| Jun 30, 2025 | 10.68 Mn |
| Mar 31, 2025 | 7.79 Mn |
| Mar 31, 2025 | 7.79 Mn |
| Dec 31, 2024 | 11.61 Mn |
| Dec 31, 2024 | 11.61 Mn |
| Sep 30, 2024 | 7.55 Mn |
| Sep 30, 2024 | 7.55 Mn |
| Jun 30, 2024 | 8.89 Mn |
| Jun 30, 2024 | 8.89 Mn |
| Mar 31, 2024 | 11.18 Mn |
| Mar 31, 2024 | 11.18 Mn |
| Dec 31, 2023 | 9.72 Mn |
| Dec 31, 2023 | 9.72 Mn |